Insmed Inc (INSM)

[ED20332]

Interesting company with NEW oral insulin pill

www.oramedpharma.com ORMP.OB


Release Source: Oramed Pharmaceuticals, Inc.


Oramed Pharmaceuticals' Receives Strong Upgrade by Respected Research Firm
Thursday June 22, 11:58 am ET


JERUSALEM--(BUSINESS WIRE)--June 22, 2006--TRI-STATE Capital (TSC), has upgraded their equity rating on ORMP. This strong upgrade comes at a time when the company reported successful pre-clinical studies of their orally ingestible soft gel insulin capsule for the treatment of type 1 and 2 diabetes. According to the American Diabetes Association, roughly 20.8 million children and adults have diabetes. Of those who have the condition, approximately 28 percent take insulin to offset the defect.

TSC is noted for their work with, account executives, analysts, portfolio managers, institutions, venture capital investors, individual investors and the media. To view the entire independent research report, please click on the attached URL: http://www.otclive.com

About Oramed Pharmaceuticals

Oramed Pharmaceuticals' is an Israeli based company focused on the development of oral delivery solutions based on proprietary technology. Diabetes is one of the most rapidly growing diseases in the world and is one that requires constant and often unpleasant monitoring and drug therapy regimen. Oramed is currently developing an orally ingestible soft gel insulin capsule for the treatment of type 1 and 2 diabetes. The Company is also pursuing the development of oral delivery solutions for other drugs and vaccines.

For additional information, please visit their web site at: www.oramedpharma.com
----------------------------------------------------------------

Oral Insulin Pill Could Bring Relief to Millions
Tuesday June 20, 8:32 am ET


NEW YORK, June 20 /PRNewswire/ -- Researchers at Hadassah-University Hospital, located in Jerusalem, have been working on a new insulin pill that could mean big changes for diabetics. The renowned team of researchers from Oramed Pharmaceuticals, led by Dr. Miriam Kidron and Professor Hanoch Bar-On, has developed a breakthrough method of delivering insulin orally.

Diabetes is an imperfection in the body's insulin production and/or action. There are two kinds of diabetes, Type 1 and Type 2. Previously called juvenile-onset diabetes, Type 1 includes up to 10 percent of all cases. Type 2 diabetes, formerly called adult-onset diabetes, accounts for over 90 percent of all cases. According to the American Diabetes Association, roughly 20.8 million children and adults have diabetes, a number that equals about 7 percent of the population. Of those who have the condition, around 28 percent take insulin to offset the defect.

Currently, some of the Type 2 diabetics take medication to enhance their body's limited ability to produce insulin. In many cases, their body's ability to produce insulin deteriorates over time. Many of them may eventually need to inject insulin. A major difference between the medication available today and what Oramed's oral insulin is expected to do is that Oramed hopes to limit the further deterioration of the body's ability to produce insulin, minimizing the need to inject insulin in the future.

At some point, the insulin pill may be able to help Type 1 diabetics and, in some cases, may even be utilized instead of the injection. Over the last decade or so, cases of Type 2 diabetes have been on the rise, with medical experts seeing marked increases in the number of children with the condition. This is believed to coincide with the obesity epidemic, as Type 2 diabetes is often related to obesity and lack of physical activity.

Oramed Pharmaceuticals is a publicly held company (OTC Bulletin Board: ORMP - News) and has recently applied to conduct Phase One clinical trials.

Contact: Jacqueline Bodnar, [e-mail], [phone]